Literature DB >> 9878123

Constitutive NF-kappaB levels in human alveolar macrophages from normal volunteers.

C F Farver1, B Raychaudhuri, L T Buhrow, M J Connors, M J Thomassen.   

Abstract

Alveolar macrophages regulate the inflammatory and immune responses within the lung through cytokine production. Nuclear factor kappa B (NF-kappaB), a transcription factor, controls the synthesis of cytokines such as interleukin 1beta, tumour necrosis factor alpha, and interleukin 8. In quiescent cells, NF-kappaB is located in the cytosol as a dimer of protein components (p50, p65) bound to an inhibitor (IkappaB). Upon activation, NF-kappaB translocates to the nucleus and binds to DNA. To determine the constitutive level of NF-kappaB activation in non-smoking normal volunteers, immunohistochemical analysis of alveolar macrophages from 29 subjects was performed with antibody directed against the p65 component of NF-kappaB. These results were confirmed in four subjects by electrophoretic mobility shift assay (EMSA). A human monocytic cell line, THP-1 with and without endotoxin stimulation was used as positive and negative controls, respectively. The mean number of positive cells was 4.1%+/-0.8. EMSA performed on whole cell extracts from four normal volunteers demonstrated minimal constitutive binding compared to the positive control. Supershift assay revealed the presence of the p65 dimer. By both immunohistochemistry and EMSA, alveolar macrophages from healthy non-smoking individuals demonstrate minimal NF-kappaB activation. Immunohistochemistry is a sensitive and quantifiable technique requiring only a minimal number of cells, and this technique may be useful in monitoring small changes in NF-kappaB activation in inflammatory diseases of the lung. Copyright 1998 Academic Press

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9878123     DOI: 10.1006/cyto.1998.0373

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  Macrophage-stimulating protein differently affects human alveolar macrophages from smoker and non-smoker patients: evaluation of respiratory burst, cytokine release and NF-kappaB pathway.

Authors:  Gabriele Gunella; Claudio Bardelli; Angela Amoruso; Ilario Viano; Piero Balbo; Sandra Brunelleschi
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

2.  In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats.

Authors:  A Serrano-Mollar; D Closa; N Prats; S Blesa; M Martinez-Losa; J Cortijo; J M Estrela; E J Morcillo; O Bulbena
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

3.  Expression of functional NK1 receptors in human alveolar macrophages: superoxide anion production, cytokine release and involvement of NF-kappaB pathway.

Authors:  Claudio Bardelli; Gabriele Gunella; Federica Varsaldi; Pietro Balbo; Elisa Del Boca; Ilaria Seren Bernardone; Angela Amoruso; Sandra Brunelleschi
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

4.  Urban airborne particle exposure impairs human lung and blood Mycobacterium tuberculosis immunity.

Authors:  Martha Torres; Claudia Carranza; Srijata Sarkar; Yolanda Gonzalez; Alvaro Osornio Vargas; Kathleen Black; Qingyu Meng; Raul Quintana-Belmares; Martha Hernandez; Jose Juan F Angeles Garcia; Victor Hugo Páramo-Figueroa; Marco Antonio Iñiguez-Garcia; Jose L Flores; Junfeng Jim Zhang; Carol R Gardner; Pamela Ohman-Strickland; Stephan Schwander
Journal:  Thorax       Date:  2019-04-29       Impact factor: 9.139

5.  M-CSF induces monocyte survival by activating NF-κB p65 phosphorylation at Ser276 via protein kinase C.

Authors:  Yijie Wang; Xiaokui Mo; Melissa G Piper; Hongmei Wang; Narasimham L Parinandi; Denis Guttridge; Clay B Marsh
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

6.  Effect of siRNA against NF-κB on sepsis‑induced acute lung injury in a mouse model.

Authors:  Li-Yan Jin; Cong-Feng Li; Guang-Fa Zhu; Chun-Ting Wu; Jun Wang; Shu-Feng Yan
Journal:  Mol Med Rep       Date:  2014-06-05       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.